COVID-19 pandemic and allergen immunotherapy-an EAACI survey

Background As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different coun...

ver descrição completa

Detalhes bibliográficos
Autores: Pfaar O, Agache I, Bonini M, Brough HA, Chivato T, Del Giacco SR, Gawlik R, Gelincik A, Hoffmann-Sommergruber K, Jutel M, Klimek L, Knol EF, Lauerma A, Ollert M, O'Mahony L, Mortz CG, Palomares O, Riggioni C, Schwarze J, Skypala I, Torres MJ, Untersmayr E, Walusiak-Skorupa J, Chaker A, Giovannini M, Heffler E, Jensen-Jarolim E, Quecchia C, Sandoval-Ruballos M, Sahiner U, Tomic Spiric V, Alvaro-Lozano M
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p22971
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22971
Access Level:acceso abierto
Palavra-chave:allergen immunotherapy (AIT)
COVID-19
pandemic
SARS-CoV-2
survey
id ES_f115b6d369bb27988fc23fed751dfed2
oai_identifier_str oai:fsjd.fundanetsuite.com:p22971
network_acronym_str ES
network_name_str España
repository_id_str
spelling COVID-19 pandemic and allergen immunotherapy-an EAACI surveyPfaar OAgache IBonini MBrough HAChivato TDel Giacco SRGawlik RGelincik AHoffmann-Sommergruber KJutel MKlimek LKnol EFLauerma AOllert MO'Mahony LMortz CGPalomares ORiggioni CSchwarze JSkypala ITorres MJUntersmayr EWalusiak-Skorupa JChaker AGiovannini MHeffler EJensen-Jarolim EQuecchia CSandoval-Ruballos MSahiner UTomic Spiric VAlvaro-Lozano Mallergen immunotherapy (AIT)COVID-19pandemicSARS-CoV-2surveyBackground As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT. Methods Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey(R)) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine. Results 417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Conclusions This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.WILEY2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22971ALLERGYISSN: 01054538ISSNe: 13989995reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p229712026-05-27T12:37:41Z
dc.title.none.fl_str_mv COVID-19 pandemic and allergen immunotherapy-an EAACI survey
title COVID-19 pandemic and allergen immunotherapy-an EAACI survey
spellingShingle COVID-19 pandemic and allergen immunotherapy-an EAACI survey
Pfaar O
allergen immunotherapy (AIT)
COVID-19
pandemic
SARS-CoV-2
survey
title_short COVID-19 pandemic and allergen immunotherapy-an EAACI survey
title_full COVID-19 pandemic and allergen immunotherapy-an EAACI survey
title_fullStr COVID-19 pandemic and allergen immunotherapy-an EAACI survey
title_full_unstemmed COVID-19 pandemic and allergen immunotherapy-an EAACI survey
title_sort COVID-19 pandemic and allergen immunotherapy-an EAACI survey
dc.creator.none.fl_str_mv Pfaar O
Agache I
Bonini M
Brough HA
Chivato T
Del Giacco SR
Gawlik R
Gelincik A
Hoffmann-Sommergruber K
Jutel M
Klimek L
Knol EF
Lauerma A
Ollert M
O'Mahony L
Mortz CG
Palomares O
Riggioni C
Schwarze J
Skypala I
Torres MJ
Untersmayr E
Walusiak-Skorupa J
Chaker A
Giovannini M
Heffler E
Jensen-Jarolim E
Quecchia C
Sandoval-Ruballos M
Sahiner U
Tomic Spiric V
Alvaro-Lozano M
author Pfaar O
author_facet Pfaar O
Agache I
Bonini M
Brough HA
Chivato T
Del Giacco SR
Gawlik R
Gelincik A
Hoffmann-Sommergruber K
Jutel M
Klimek L
Knol EF
Lauerma A
Ollert M
O'Mahony L
Mortz CG
Palomares O
Riggioni C
Schwarze J
Skypala I
Torres MJ
Untersmayr E
Walusiak-Skorupa J
Chaker A
Giovannini M
Heffler E
Jensen-Jarolim E
Quecchia C
Sandoval-Ruballos M
Sahiner U
Tomic Spiric V
Alvaro-Lozano M
author_role author
author2 Agache I
Bonini M
Brough HA
Chivato T
Del Giacco SR
Gawlik R
Gelincik A
Hoffmann-Sommergruber K
Jutel M
Klimek L
Knol EF
Lauerma A
Ollert M
O'Mahony L
Mortz CG
Palomares O
Riggioni C
Schwarze J
Skypala I
Torres MJ
Untersmayr E
Walusiak-Skorupa J
Chaker A
Giovannini M
Heffler E
Jensen-Jarolim E
Quecchia C
Sandoval-Ruballos M
Sahiner U
Tomic Spiric V
Alvaro-Lozano M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv allergen immunotherapy (AIT)
COVID-19
pandemic
SARS-CoV-2
survey
topic allergen immunotherapy (AIT)
COVID-19
pandemic
SARS-CoV-2
survey
description Background As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT. Methods Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey(R)) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine. Results 417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Conclusions This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22971
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22971
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv ALLERGY
ISSN: 01054538
ISSNe: 13989995
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424095128453120
score 15,812429

Registos relacionados